C7aeae20-figure-01 (C7aeae20 Figure 01)
Not available.*
Ticagrelor Tablet, Film Coated
Product Images NDC 43547-657
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 43547-657). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Solco Healthcare U.s., Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
C7aeae20-figure-02 (C7aeae20 Figure 02)
C:\users\ra\desktop\untitled.jpg (C7aeae20 Figure 03)
C7aeae20-figure-05 (C7aeae20 Figure 04)
C7aeae20-figure-06 (C7aeae20 Figure 05)
Figure7 (C7aeae20 Figure 06)
This text provides information on dose adjustments for Ticagrelor (AR-C124010XX) based on intrinsic factors such as age, gender, ethnicity, renal disease status, and hepatic impairment. The data includes recommendations for dose adjustments or no adjustment for different conditions or demographics. It also mentions the lack of studies involving Ticagrelor tablets in patients with moderate or severe hepatic impairment.*
Figure-08 (C7aeae20 Figure 07)
This text provides information on the mean effect and 90% Confidence Interval interactions of the drug Ticagrelor with various interacting drugs. It categorizes the recommendations for Strong CYP3A4 inhibitors like Ketoconazole and Potent CYP3A4 inducers like Rifampin as "Avoid concomitant use," while suggesting no dose adjustment for Moderate CYP3A4 inhibitors such as Diltiazem. Additionally, guidelines are given for other medications like Aspirin, Desmopressin, Heparin, and Enoxaparin regarding dose adjustments or concomitant use. The interaction information for P-gP and CYP3A inhibitors like Cyclosporine, Morphine, and Fentanyl is also detailed, with further reference to Section 7.4 for specific details.*
C7aeae20-figure-09 (C7aeae20 Figure 08)
This text provides information on interactions between Ticagrelor and several other drugs such as Simvastatin, Atorvastatin, Lovonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine, specifying the recommended dose adjustments and potential effects on drug levels. It also mentions to monitor digoxin levels when initiating or changing Ticagrelor therapy.*
C7aeae20-figure-10 (C7aeae20 Figure 09)
C7aeae20-figure-11 (C7aeae20 Figure 10)
C7aeae20-figure-12 (C7aeae20 Figure 11)
Figure 13 (C7aeae20 Figure 12)
90 mg 60 Ct (C7aeae20 Figure 14)
Each tablet contains 90 mg of ticagrelor. The usual adult dosage should be confirmed by referring to the package insert. Remember to keep this medication out of the reach of children. Store it at a temperature between 20°C - 25°C (68°F - 77°F), with permitted excursions to 15°C - 30°C (59°F - 86°F) as per USP Controlled Room Temperature guidelines. You can access the Medication Guide online at www.solcohealthcare.com/medguide/ticagrelor-tablets.pdf. This medication is manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd. in China and distributed by Solco Healthcare US, LLC in the USA.*
Figure4 (Image 02)
Figure17 (Image 05)
Figure 18 (Image 06)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
